Foresite Capital Management VI LLC
In its 13F for Q3 2025 (holdings as of September 30, 2025, filed November 14, 2025), Foresite Capital Management VI LLC reported 12 stock positions worth $258.9 million. Its top holding was CG Oncology (CGON) at 34.6% of the portfolio, followed by Rapt Therapeutics (RAPT, 15.6%) and Centessa Pharmaceuticals (CNTA, 12.3%). Compared with Q2 2025, it opened 1 new position, sold out of 9 and added to 3. The biggest buy was Verastem (VSTM, shares +105%) and the biggest sale an exit from Bicara Therapeutics (BCAX).
- Most Recent 13F
- Q2 2026
- Location
- WEST HOLLYWOOD, CA
- CIK
- 0002013341
- Portfolio Value
- $258.9M (Q3 2025)
- SEC Filing
- 0001104659-25-112509 ↗ filed Nov 14, 2025
Holdings Value
Holdings 12 stocks · $258.9M
| CGON CG Oncology Inc. | 34.57% | 2,221,474 | $89.5M | No change |
| RAPT Rapt Therapeutics Inc. | 15.57% | 1,562,500 | $40.3M | No change |
| CNTA Centessa Pharmaceuticals Ltd. | 12.31% | 1,314,019 | $31.9M | Add +4.8% |
| VSTM Verastem Inc. | 8.92% | 2,615,120 | $23.1M | Add +104.9% |
| ALMS Alumis Inc. | 6.55% | 4,247,670 | $16.9M | No change |
| DNLI Denali Therapeutics Inc. | 5.61% | 1,000,000 | $14.5M | New |
| CRVS Corvus Pharmaceuticals Inc. | 4.93% | 1,731,233 | $12.8M | No change |
| AKRO Akero Therapeutics Inc. | 4.49% | 244,900 | $11.6M | No change |
| KYMR Kymera Therapeutics Inc. | 3.20% | 146,332 | $8.3M | No change |
| HNGE Hinge Health Inc. Class A | 2.56% | 135,000 | $6.6M | No change |
| RNAM Avidity Biosciences Inc. | 0.67% | 40,000 | $1.7M | No change |
| CASIF Casi Pharmaceuticals Inc. | 0.63% | 979,956 | $1.6M | Add +24.5% |
Portfolio Sells Q2 2025 → Q3 2025
| BCAX Bicara Therapeutics Inc. | Sold out | 0.00% | −4.96 |
| EWTX Edgewise Therapeutics Inc. | Sold out | 0.00% | −4.31 |
| XENE Xenon Pharmaceuticals Inc. | Sold out | 0.00% | −2.82 |
| CGEM Cullinan Therapeutics Inc. | Sold out | 0.00% | −2.51 |
| GPCR Structure Therapeutics Inc. | Sold out | 0.00% | −2.45 |
| ALLO Allogene Therapeutics Inc. | Sold out | 0.00% | −1.83 |
| IDYA Ideaya Biosciences Inc. | Sold out | 0.00% | −1.71 |
| SYRE Spyre Therapeutics Inc. | Sold out | 0.00% | −0.59 |
| VRDN Viridian Therapeutics Inc. | Sold out | 0.00% | −0.02 |
Portfolio Buys Q2 2025 → Q3 2025
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 23 | $642.6M | CGON, ALMS, SPTX, DNLI, CLDX |
| Q1 2026 | 17 | $460.3M | CGON, ALMS, CNTA, CRVS, DNLI |
| Q4 2025 | 12 | $330.8M | CGON, RAPT, ALMS, CNTA, VSTM |
| Q3 2025 | 12 | $258.9M | CGON, RAPT, CNTA, VSTM, ALMS |
| Q2 2025 | 20 | $177.9M | CGON, CNTA, AKRO, ALMS, RAPT |
| Q1 2025 | 14 | $182.5M | CGON, ALMS, CNTA, RAPT THERAPEUTICS INC, AKRO |
| Q4 2024 | 14 | $224.4M | CGON, ALMS, CNTA, RAPT THERAPEUTICS INC, BCAX |